CD19 and Miyoshi myopathy: On the other hand, MM patients treated with non-BCMA directed CAR T cells such as CD138, CD19, NKG2D, and kappa light chain have not shown any severe ICANS after the treatment, probably because these products can only achieve limited CAR T cell activation and clinical efficacy (46, 50, 66, 67).